INTRODUCTION Atherosclerosis (AS), a chronic inflammatory disease of the arterial wall characterized by gradual build-up of arterial plaque, is the main cause of cardiovascular disease (CVD) [1, 2]. Aging is a major, independent risk factor for AS [3]. Macrophages are main components of the inflammatory plaque and promote AS development across its different stages [4-6]. Accumulating data indicates that pyroptosis, a highly inflammatory form of programmed cell death usually triggered in immune cells upon infection by intracellular pathogens, occurs also in AS-associated macrophages and contributes importantly to plaque instability [7, 8]. Therefore, therapies aimed at inhibiting macrophage pyroptosis may reduce the morbidity and mortality associated with AS.